title: Efficacy and safety of nucleoside analogues in preventing vertical transmission of the hepatitis B virus from father to infant.
abstract: We examined the efficacy and safety of nucleoside analogues in preventing the vertical transmission of hepatitis B virus (HBV) from father to infant. We included 201 patients who visited the liver clinic of our hospital. The patients were positive for HBV surface antigen (HBsAg), HBeAg, anti-HBc, and HBV DNA; 189 patients (94%) had abnormal liver function. In all couples, the fathers were HBV DNA-negative and had normal liver function, and the mothers were anti-HB-positive before pregnancy. The control group comprised 188 couples who visited our hospital during the same time period. The fathers in the control group were positive for HBsAg, HBeAg, anti-HBc, and HBV DNA. The mothers were HBsAg-negative and anti-HBs-positive. No infants in the case group were HBsAg-positive and HBV DNA-positive, and all were anti-HBs-positive, indicating that father to infant HBV vertical transmission was prevented in the case group. In the control group, 147 of 188 newborns (78.2%) were anti-HBs-positive at birth, 28 (14.9%) were HBV DNA-positive, and 19 (10.1%) were HBsAg-positive. A significant difference was observed between the two groups. No statistically significant difference was observed in the gestational age, birth weight, birth length, 1-min and 8-min Apgar score, jaundice, other internal and surgical diseases, delivery mode, and other birth information between the neonates born to couples in the case and control groups; there were no fetal malformations and stillbirths in the two groups. Our results showed that administration of antiretroviral therapy to HBV DNA-positive fathers before pregnancy can cause a decrease in the viral load and prevent father to infant HBV vertical transmission. The use of antiviral nucleoside analogues before pregnancy was safe in fathers, and the fathers who wanted children could continue to use anti-viral therapy. The sample size in our study was small, and further studies with a large sample size and longer follow-up time are required for determining the use of nucleoside analogues from the point view of prenatal and postnatal care.
authors.affiliation: Third Hospital Liver Disease Center of Qinhuangdao, Qinhuangdao, Hebei, China caolihua_clh@163.com.
authors.forename: L-H
authors.initials: LH
authors.lastname: Cao
authors.affiliation: Third Hospital Liver Disease Center of Qinhuangdao, Qinhuangdao, Hebei, China.
authors.forename: P-L
authors.initials: PL
authors.lastname: Zhao
authors.affiliation: Third Hospital Liver Disease Center of Qinhuangdao, Qinhuangdao, Hebei, China.
authors.forename: Z-M
authors.initials: ZM
authors.lastname: Liu
authors.affiliation: Women and Children's Hospital of Qinhuangdao, Qinhuangdao, Hebei, China.
authors.forename: S-C
authors.initials: SC
authors.lastname: Sun
authors.affiliation: Third Hospital Liver Disease Center of Qinhuangdao, Qinhuangdao, Hebei, China.
authors.forename: D-B
authors.initials: DB
authors.lastname: Xu
authors.affiliation: Third Hospital Liver Disease Center of Qinhuangdao, Qinhuangdao, Hebei, China.
authors.forename: J-D
authors.initials: JD
authors.lastname: Zhang
authors.affiliation: Third Hospital Liver Disease Center of Qinhuangdao, Qinhuangdao, Hebei, China.
authors.forename: Z-H
authors.initials: ZH
authors.lastname: Shao
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers; D016022:Case-Control Studies; D005220:Fathers; D005260:Female; D006509:Hepatitis B / Q000175:diagnosis / Q000188:drug therapy* / Q000635:transmission* / Q000821:virology; D006515:Hepatitis B virus / Q000235:genetics; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D008297:Male; D011247:Pregnancy; D011248:Pregnancy Complications; D012307:Risk Factors
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers